PTGX — Protagonist Therapeutics, Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1377121 ·
Last close
$131.42
Market Cap
$8.45B
52W High
$141.10
52W Low
$92.75
ADV30
868,613
Next earnings
2026-05-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 56,368,000 | — | -3,648,000 | 3,783,000 | 697,459,000 | 193,712,000 | 41,986,000 |
| Dec 2025 | 7,437,000 | — | -50,355,000 | -44,384,000 | 668,188,000 | 128,390,000 | 53,481,000 |
| Sep 2025 | 4,712,000 | — | -46,421,000 | -39,339,000 | 701,688,000 | 113,713,000 | 56,251,000 |
| Jun 2025 | 5,546,000 | — | -42,041,000 | -34,771,000 | 718,006,000 | 168,543,000 | 49,988,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-116,635,000
Investing CF
$135,962,000
Financing CF
$34,795,000
CapEx
$-1,260,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-466,888,000
Inventory
—
Receivables
$57,122,000
ST Investments
$354,074,000
EBIT TTM
$-142,465,000
Pretax Income TTM
$-115,375,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$74,063,000
EBITDA
$-141,016,992
Free Cash Flow
$-77,664,624
Enterprise Value
$8,313,807,360
Total Cash
$547,785,984
Total Debt
$9,776,000
Shares Out
64,311,373
Trailing EPS
$-1.82
Book Value
$10.21
ROE
-17.1%
ROA
-12.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,016,000 | -158,127,000 | -130,149,000 | 668,188,000 | 53,481,000 | — | 57,671,000 |
| Dec 2024 | 434,433,000 | 252,843,000 | 275,188,000 | 744,725,000 | 69,430,000 | — | 184,152,000 |
| Dec 2023 | 60,000,000 | -93,652,000 | -78,955,000 | 357,951,000 | 21,274,000 | — | -70,236,000 |
| Dec 2022 | 26,581,000 | -131,373,000 | -127,393,000 | 247,928,000 | 32,320,000 | — | -108,137,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,084,000
OpCashFlow TTM
$0
Assets (Latest)
$93,990,000
Forward EPS
$-0.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | $8.49B | $97.74 | — |
| ALKS | Alkermes plc. | $8.66B | $51.94 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.74B | $57.12 | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.85B | $83.58 | — |
| PRAX | Praxis Precision Medicines, Inc. | $9.06B | $324.99 | — |
News headlines (Yahoo Finance, 1h cache)
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review
2026-07-09 16:10 · Yahoo
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued
2026-07-09 14:14 · Yahoo
New Strong Buy Stocks for July 9th
2026-07-09 08:53 · Yahoo
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?
2026-07-08 16:18 · Yahoo
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
2026-07-08 14:30 · Yahoo
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
2026-07-08 14:29 · Yahoo
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock
2026-07-02 14:15 · Yahoo
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-07-01 20:05 · Yahoo
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
2026-06-01 11:05 · Yahoo
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
2026-05-30 00:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.